Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota


The principal research objective is to determine the impact of antibiotic use on the risk of developing long term bowel symptoms after infection with the germ Campylobacter.

Full Title of Study: “An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2017

Detailed Description

The secondary research objectives are: – To investigate how the particular strain of the Campylobacter germ that causes the infection, and the strength of the immune response that it stimulates in the bowel, affect the risk of long term bowel symptoms. – To explore what changes occur after Campylobacter infection in the bacteria that usually live in the large bowel (microbiota) and the chemicals that they produce (short-chain fatty acids) when they digest nutrients. We will look for differences between people who recover fully and people who have long term bowel symptoms.

Arms, Groups and Cohorts

  • Post-Campylobacter
    • Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured

Clinical Trial Outcome Measures

Primary Measures

  • Yes/ no: Post-Infective bowel dysfunction (PI-BD)
    • Time Frame: 12 weeks after microbiological diagnosis of infection
    • This will be defined by response to the question “have your bowels returned to normal since your Campylobacter infection?”

Secondary Measures

  • Yes/ No: Post-Infective irritable bowel syndrome (PI-IBS)
    • Time Frame: 12 weeks after microbiological diagnosis of infection
    • Symptoms meeting Rome III criteria for Irritable Bowel Syndrome (other than 6 month duration)

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 – Clinical syndrome suggestive of intestinal infection, including symptoms such as new onset of abdominal pain, vomiting, diarrhoea, blood in stools, fever – Submission of stool sample to Nottingham University Hospitals Microbiology Laboratory for investigation of these symptoms – Campylobacter sp. cultured by selective media (standard clinical practice) from this stool sample Exclusion Criteria:

  • Pregnancy declared by the candidate – History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to: – Inflammatory Bowel Disease – Coeliac Disease – Pancreatitis – Gallstone disease (biliary colic, cholecystitis) – Diverticulitis – Cancer of the gastrointestinal tract – Irritable Bowel Syndrome – Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder – Intestinal stoma – Habitual use of opiate analgesics likely to alter bowel function e.g. morphine – Use of antibiotics in the preceding four weeks other than for treatment of index infection. – Use of purgative products/ high dose laxatives for bowel preparation in the four weeks prior to index infection. – Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration – Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting memory and understanding – Declared participation in any medical trials in the past 3 months – Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Nottingham
  • Collaborator
    • Nottingham University Hospitals NHS Trust
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Robin C Spiller, MSc MD FRCP, Study Chair, University of Nottingham
    • Giles AD Major, BM BCh MRCP, Principal Investigator, University of Nottingham
    • Mathew Diggle, MSc PhD, Study Director, Nottingham University Hospitals NHS Trust
    • Richard Puleston, MBBS PhD, Study Director, University of Nottingham
    • Miranda Lomer, PhD RD, Study Director, King’s College London

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.